Search Results

Electron cryo-microscopy (cryo-EM) is a powerful technique for the structural characterization of biological macromolecules, enabling high-resolution analysis of targets once inaccessible to structural interrogation. In recent years, pharmaceutical companies have begun to utilize cryo-EM for structure-based drug design. Structural analysis of integral membrane proteins, which comprise a large proportion of druggable targets and pose particular challenges for X-ray crystallography, by cryo-EM has enabled insights into important drug target families such as G protein-coupled receptors (GPCRs), ion channels, and solute carrier (SLCs) proteins. Structural characterization of biologics, such as vaccines, viral vectors, and gene therapy agents, has also become significantly more tractable. As a result, cryo-EM has begun to make major impacts in bringing critical therapeutics to market. In this review, we discuss recent instructive examples of impacts from cryo-EM in therapeutics design, focusing largely on its implementation at Pfizer. We also discuss the opportunities afforded by emerging technological advances in cryo-EM, and the prospects for future development of the technique. Read full article

Apart from G proteins, GPCRs engage other effectors for signaling modulation. receptor internalization. β-Arrestins facilitate this process by interacting with adapter protein 2 (AP This approach reveals binding interfaces and interactions between GPCRs and β-arrestins, paving the way This includes proteins like AP-2 and clathrin, vital for internalization, as well as MAPK cascade kinases

October 2022 High hedgehog signaling is transduced by a multikinase-dependent switch controlling the apico-basal Together, these results link the morphogenetic effects of HH to the apico-basal distribution of SMO and

Melanocortin 3 receptor (MC3R) is a G-protein coupled receptor (GPCR) that is defined as a regulator of appetite In addition to its function about weight gain and appetite control mechanisms of MC3R, recent studies point out the importance of the MC3R regulations in three main concepts: 1) its impact on weight and appetite

Mechanism of enhanced sensitivity of mutated β-adrenergic-like octopamine receptor to amitraz in honeybee Apis insecticides for effective control of pest infestation of Varroa destructor mite, a devastating parasite of Apis

He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as multiple New Drug (NDA) and Supplemental New Drug Applications (SNDA). #biotech #lifesciences #appointment #GPCR #Oncology" Read more at the source #DrGPCR #GPCR #IndustryNews

October 2022 "Background: Uncoupling proteins (UCPs) are unpaired electron carriers that uncouple oxygen intake by the electron transport chain from ATP production in the inner membrane of the mitochondria. The physiological activities of UCPs have been hotly contested, and the involvement of UCPs in the pathogenesis and progression of diabetes mellitus is among the greatest concerns. UCPs are hypothesised to be triggered by superoxide and then reduce mitochondrial free radical production, potentially protecting diabetes mellitus patients who are experiencing oxidative stress. Objectives: The objectives of the study are to find out the newest ways to treat diabetes mellitus through protein uncoupling." Read more at the source #DrGPCR #GPCR #IndustryNews

September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies." Read more at the source #DrGPCR #GPCR #IndustryNews

GPCR, we believe the same principle applies to building a better experience  for our online community | PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural and Functional Approaches Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Summit April 1 - 5, 2025 | XXIII GEM Meeting in 2025 April 3 - 6, 2025 | ASPET 2025 April 14 - 17, 2025 | 20th Drug Discovery Chemistry April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR

| PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural and Functional Approaches February 15 - 19, 2025 | BPS 2025 February 16 - 21, 2025 | Harnessing the Power of Advanced Multimodal Approaches Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Summit April 1 - 5, 2025 | XXIII GEM Meeting in 2025 April 3 - 6, 2025 | ASPET 2025 April 14 - 17, 2025 | 20th Drug Discovery Chemistry April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR

A with Sean McClain, Founder & CEO, and Zach Jonasson, CFO & CBO at Absci Octant: A Next Generation Approach | PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural and Functional Approaches Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Summit April 1 - 5, 2025 | XXIII GEM Meeting in 2025 April 3 - 6, 2025 | ASPET 2025 April 14 - 17, 2025 | 20th Drug Discovery Chemistry April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR

GPCR News from November 18th to 24th, 2024 Industry News Amgen Announces Senior Executive Research Appointment | PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural and Functional Approaches Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Summit April 1 - 5, 2025 | XXIII GEM Meeting in 2025 April 3 - 6, 2025 | ASPET 2025 April 14 - 17, 2025 | 20th Drug Discovery Chemistry April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR

This approach requires careful planning, but it saves you from the frustration of ambiguous data and This approach not only ensures that you remain on top of your findings but also makes the thesis-writing

| PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural and Functional Approaches Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Summit April 1 - 5, 2025 | XXIII GEM Meeting in 2025 April 3 - 6, 2025 | ASPET 2025 April 14 - 17, 2025 | 20th Drug Discovery Chemistry April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR pathways Divergent roles of DRY and NPxxY motifs in selective activation of downstream signalling by the apelin

| PepTalk 2025 January 25 - 29, 2025 | SLAS 2025 February 15 - 16, 2025 | Structural and Functional Approaches February 15 - 19, 2025 | BPS 2025 February 16 - 21, 2025 | Harnessing the Power of Advanced Multimodal Approaches Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Summit April 1 - 5, 2025 | XXIII GEM Meeting in 2025 April 3 - 6, 2025 | ASPET 2025 April 14 - 17, 2025 | 20th Drug Discovery Chemistry April 24 - 27, 2025 | American Physiology Summit 2025 April 25 - 30, 2025 | AACR

For example, a DMS approach has been conducted to reveal the functional importance of each residue in DMS provides a proactive approach to this problem by predicting potential resistance mutations before Limitations Deep mutational scanning encounters several constraints that affect its broad applicability Additionally, DMS is not universally applicable to all proteins; it struggles with proteins that lack Another promising development is the application of DMS to a wider array of biological systems, including

PepTalk 2025 NEW January 25 - 29, 2025 | SLAS 2025 NEW February 15 - 16, 2025 | Structural and Functional Approaches 15 - 19, 2025 | BPS 2025 NEW February 16 - 21, 2025 | Harnessing the Power of Advanced Multimodal Approaches March 12 - 14, 2025 | NextGen Biomed 2025 NEW March 25 - 28, 2025 | 10th German Pharm-Tox Summit NEW April 1 - 5, 2025 | XXIII GEM Meeting in 2025 NEW April 3 - 6, 2025 | ASPET 2025 NEW   April 14 - 17, 2025 | 20th Drug Discovery Chemistry NEW   April 24 - 27, 2025 | American Physiology Summit 2025 NEW April

mice Orphan GPCRs in Neurodegenerative Disorders: Integrating Structural Biology and Drug Discovery Approaches

Participants will acquire knowledge in: The powerful applications of new cellular assays to determine November 14th: The Application of GPCR Ligand Kinetics to Candidate Design.

findings that enhance our understanding of GPCRs' roles in immune function and potential therapeutic applications

Allow registrants to appreciate the incredible versatility of GPCRs and how small molecules can affect Apply unique pharmacologic assays and unconventional ligands to unveil GPCR activities.

Registrants will learn: The powerful applications of new cellular assays to determine GPCR ligand behavior November 14th : The Application of GPCR Ligand Kinetics to Candidate Design. exceptional faculty members who adeptly simplify the intricacies of GPCR pharmacology for practical application into the   Classified GPCR News from September 30th to October 6th, 2024 Industry News Nxera Pharma appoints

After discussing the fundamentals and applications of mutagenesis in GPCR studies (Lu, 2024), a case study is essential to deepen understanding and apply this approach in a practical context. Rational Drug Design One immediate application of this research lies in rational drug design . Allosteric modulators offer a promising approach for developing drugs that enhance or inhibit receptor Personalised Medicine Another significant application of these findings is in personalised   medicine

Registrants will learn: The powerful applications of new cellular assays to determine GPCR ligand behavior November 14th : The Application of GPCR Ligand Kinetics to Candidate Design. content and our exceptional professors' ability to simplify the complexity of GPCR pharmacology and apply with Novartis to Discover and Develop Protein Therapeutics with Generative AI Nxera Pharma receives approval and a Class A GPCR Regulating Hunger and Satiety OMass Therapeutics Expands Development Team with Key Appointments

AlphaFold2 uses an AI-driven approach that eliminates the need for structural templates, allowing it

., Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.  

Affordable & Unique Learning Experience Our budget-friendly courses offer a unique approach to mastering

Learning Experience Dive deep into pharmacology with our budget-friendly courses that offer a unique approach drugs, including the role of machine learning, new biophysical techniques, and medicinal chemistry approaches Best Startup’ Award: Pioneering GPCR-Driven Immunotherapies in Cancer Treatment Structure Therapeutics Appoints